| Document |
Document Title |
|
WO/2021/058648A1 |
A process for purification of phytosterols, said process comprising, a. providing a liquid mixture comprising a phytosterol, lower alcohol, wherein the lower alcohol is present in an amount of from 25 to 800% by weight, based on the amou...
|
|
WO/2021/058646A1 |
The presently claimed invention relates to a process for the production and purification of sterols from oil distillates or oil distillation residues, in particular from the latter. Specifically, the presently claimed invention relates t...
|
|
WO/2021/046678A1 |
A method for synthesising chenodeoxycholic acid and an application therefor, relating to the technical field of pharmaceutical and chemical product synthesis, and used for solving the technical problem of the high production costs of exi...
|
|
WO/2021/043845A1 |
In its first aspect, the disclosure concerns a process for providing an extract of phytosterols and stanols from tall oil pitch with the steps of (b) saponifying tall oil pitch by addition of a basic compound; (c) extracting the saponifi...
|
|
WO/2021/036998A1 |
Provided are a novel bile acid derivative for treating fatty liver disease, a pharmaceutical composition thereof, and a use in the preparation of a medicine for treating and improving diseases and symptoms mediated or caused by FXR or TG...
|
|
WO/2021/033766A1 |
The purpose of the present invention is to provide a novel lithocholic acid derivative having sufficient vitamin D3 activity. A compound represented in general formula (I), a salt thereof, or a prodrug thereof is provided. (R1 and R2 ind...
|
|
WO/2021/016954A1 |
Disclosed are a 3-acetyl-5-hydroxy-B-norcholesterol-6-(N-methyl)thiosemicarb
azone, a preparation method therefor and the use thereof, and structural formula (I) of the 3-acetyl-5-hydroxy-B-norcholesterol-6-(N-methyl)thiosemicarb
azone. ...
|
|
WO/2021/005618A1 |
The present invention discloses novel method for synthesizing vegan cholesterol and vitamin D3 from inexpensive crude phytosterol.
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/252713A1 |
The present invention relates to the preparation of a hydrophobic medicinal auxiliary material and a drug-loaded fat emulsion, and in particular to a hydrophobic auxiliary material with the structural formula as shown below, wherein R is...
|
|
WO/2020/244483A1 |
Provided are novel chemical compounds in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the...
|
|
WO/2020/240483A1 |
The present invention relates to, in part, a combination therapy of a polyhydroxylated bile acid and a famesoid X receptor agonist. The present invention also provides, in part, a pharmaceutical composition comprising a famesoid X recept...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/230159A1 |
The invention discloses an improved process for production of vitamin D3 from 7- dehydrocholesterol (7- DHC) and to a simple process for recovery unreacted 7-DHC for further reuse. The invention further describes a process for isolation ...
|
|
WO/2020/221113A1 |
Provided by the present invention is a preparation method for momordin Ib, comprising: first, mixing a plant containing a triterpene saponin derivative having the structural unit shown in formula (I) or a plant extract containing a trite...
|
|
WO/2020/218383A1 |
Development of a novel GLP-secretagogue for promoting secretion of GLP-1 is anticipated. The present invention provides a GLP-secretagogue characterized by containing 2 ppm or more of mogroside.
|
|
WO/2020/214919A1 |
The present invention pertains to a method for inhibiting, reducing or reversing atherosclerosis or a composition or pharmaceutical composition for preventing or treating an atherosclerotic disease containing a preparation of Antrodia ca...
|
|
WO/2020/201968A2 |
The present disclosure describes that high purity cholesterol is obtained by the processes of the invention without any further purification step, such as a crystallizing step from a solvent, but rather by distilling steps alone. The dis...
|
|
WO/2020/201999A2 |
Described are various embodiments of a pupil tracking system and method, and digital display device and digital image rendering system and method using same. In one embodiment, a computer-implemented method for dynamically adjusting rend...
|
|
WO/2020/187298A1 |
The present invention relates to a method for preparing a chenodeoxycholic acid derivative. Particularly, disclosed is a method for carrying out one-pot reduction on a compound represented by formula (Ⅵ), i.e., 3α-hydroxyl-ethidene-7-...
|
|
WO/2020/189734A1 |
Provided is a compound or salt thereof represented by formula (I) below [In formula (I), R1 represents –COOH or –CY1Y2OH (where, Y1 and Y2 each represent a hydrogen atom or a detectable marker), A1 represents a sugar or an aglycone, ...
|
|
WO/2020/177240A1 |
The present application relates to the field of drug synthesis and specifically relates to chenodeoxycholic acid and a preparation method therefor. The preparation method for the chenodeoxycholic acid comprises the following steps: formi...
|
|
WO/2020/176436A1 |
The present invention pertains to a composition for preparing a medicament for preventing and/or treating a virus infection, especially a hepatitis B virus infection and/or a herpes simplex virus, and uses thereof.
|
|
WO/2020/172313A1 |
The invention provides compounds as allosteric modulators that are useful as sweet flavor enhancers. The present invention also includes ingestible compositions comprising the present compounds and methods of enhancing the sweet taste of...
|
|
WO/2020/169643A1 |
The present invention relates to the diethylamine salt of 3a- tetrahydropyranyloxy-6a-ethyl-7a-hydroxy-53-cholanic acid (I), which is a new intermediate in the synthesis of obeticholic acid, to the use of said diethylamine salt in the sy...
|
|
WO/2020/163201A1 |
The present application relates to methods of treating or preventing an intestinal inflammatory disease or condition (e.g., intestinal ischemia reperfusion injury) in a subject in need thereof, comprising administering a therapeutically ...
|
|
WO/2020/119836A8 |
A process for preparing obeticholic acid, wherein the 7-keto-litocholic acid amide of formula (II), where R1, R2 are a C1-C6 n-alkyl, or together a C5-C6 cycle and the protecting group on the hydroxyl in position 3 is a carbamoyl with th...
|
|
WO/2020/117945A8 |
The compositions and methods provided herein are related, in part, to the discovery of cholic acid 7-sulfate as a treatment for diabetes. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), or an infl...
|
|
WO/2020/136292A1 |
The present invention relates to compounds that can be defined as compounds derived from lithocholic acid and the metabolites thereof. For this reason, the compounds of the invention are named using the steroid numbering system. More par...
|
|
WO/2020/125825A1 |
The present technical solution relates to compounds of general formula (I), wherein X is independently H or OH, while at least one X is OH, for use as a medicament, particularly in the treatment or prevention of cellular growth and regen...
|
|
WO/2020/068004A3 |
A new lanostane triterpenoid (24E)-3β-acetoxy-15α-propionyloxylanosta-7,9( 11 ),24-trien-26-oic acid (GA003), is synthesized by acylation reaction of a naturally occurring fungal metabolite, (24E)-3β-acetoxy-15α-hydroxylanosta-7,9( 1...
|
|
WO/2020/128514A1 |
2-Fluorinated bile acid compounds of general formula (I) wherein at least one of R1 and R2 represents F and the other is chosen 3 from H and F and wherein R3 is as defined herein; are of use in the treatment and prevention of neurodegene...
|
|
WO/2020/131058A1 |
Disclosed is a method for enhancing the activity of telomerase using a composition containing ecdysterone. The invention also discloses the use of a composition containing ecdysterone and/or an extract containing ecdysterone, isolated fr...
|
|
WO/2020/121140A1 |
The present invention relates to fractionation of crude tall oil, which originates from the Kraft process black liquor. In the method,according to the present invention, simulated moving bed (SMB) chromatography is used to efficiently se...
|
|
WO/2020/119836A1 |
A process for preparing obeticholic acid, wherein the 7-keto-litocholic acid amide of formula (II), where R1, R2 are a C1-C6 n-alkyl, or together a C5-C6 cycle and the protecting group on the hydroxyl in position 3 is a carbamoyl with th...
|
|
WO/2020/117945A1 |
The compositions and methods provided herein are related, in part, to the discovery of cholic acid 7-sulfate as a treatment for diabetes. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), or an infl...
|
|
WO/2020/104356A1 |
The present invention relates to 7-dehydrocholesterol-hemihydrate. It has been found that the formation of 7-dehydrocholesterol-hemihydrate offers an efficient method of increasing the storage stability of 7-dehydrocholesterol, respectiv...
|
|
WO/2020/104353A1 |
The present invention relates to 7-dehydrocholesterol-hemimethanolate. It has been found that the formation of 7-dehydrocholesterol-hemimethanolate offers an efficient method of increasing the storage stability of 7-dehydrocholesterol, r...
|
|
WO/2020/095888A1 |
Provided is a method for producing high-purity cholesterol which does not contain a substantial amount of desmosterol, said method comprising reacting cholesterol mixed with desmosterol with a halogenating reagent and water and then sepa...
|
|
WO/2019/161211A3 |
Methods useful for reducing or preventing hepatic steatosis and NASH are provided herein. Such methods may comprise administering to a subject in need thereof an FXR agonist in combination with an amount of a branched amino acid in free ...
|
|
WO/2019/228602A8 |
The invention relates to a process for recovering sterols and a fraction rich in fatty acids and resin acids from tall oil pitch, said process comprising a) saponifying the tall oil pitch with an alkali to hydrolyse esters included in th...
|
|
WO/2020/076815A1 |
Steroid compounds are disclosed that have a formula represented by the following: (I) and wherein R1, R2, R3a, R3b, R4a, R4b, R5, R6a, R6b, R7, R8, and n are as described herein. The compounds may be prepared as pharmaceutical compositio...
|
|
WO/2020/061317A1 |
The invention relates to sterol esters and methods for producing purified sterols that can be utilized in methods for producing a lipid nanoparticle.
|
|
WO/2020/061332A1 |
The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of compositions comprising mRNA and a lipid nanoparticle comprising a compound of the invention and an ionizable lipid.
|
|
WO/2020/045570A1 |
Provided are: a novel compound that forms a self-assembly; the self-assembly; production methods for the compound and the self-assembly; and pharmaceutical use of the compound and the self-assembly. The compound is represented by formula...
|
|
WO/2020/039449A1 |
The present invention relates to an improved process for the preparation of Obeticholic acid and intermediates used in the process thereof. The invention also relates to a solid form of tertiary butylamine salt of Obeticholic acid and te...
|
|
WO/2020/030737A1 |
The present invention relates to isolithocholic acid (3ß-hydroxy-5ß-cholan-24-oic acid, iso-LCA) and isoallolithocholic acid (3ß-hydroxy-5α-cholan-24-oic acid) and their deuterated analogs for preventing or treating Clostridium diffi...
|
|
WO/2020/025942A1 |
Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic ...
|
|
WO/2020/020728A1 |
Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; saidcarbocyclic or heterocyclic ring being op...
|
|
WO/2020/020306A1 |
The present invention relates to a crystal form of a compound of formula (I) and an application thereof in preparing a drug for treating an ophthalmic disease.
|
